Drug Profile
Research programme: ANPH 119 - Ancile
Latest Information Update: 18 Sep 2006
Price :
$50
*
At a glance
- Originator Ancile Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cardiovascular disorders
Most Recent Events
- 18 Sep 2006 Discontinued - Preclinical for Cardiovascular disorders in USA (unspecified route)
- 17 Jul 2001 New profile
- 17 Jul 2001 Preclinical development for Cardiovascular disorders in USA (Unknown route)